RNA vs. ITCI, SMMT, MRNA, RDY, CTLT, SRPT, QGEN, PCVX, ASND, and ROIV
Should you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.
Avidity Biosciences vs.
Intra-Cellular Therapies (NASDAQ:ITCI) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.
Intra-Cellular Therapies currently has a consensus price target of $100.31, suggesting a potential downside of 20.52%. Avidity Biosciences has a consensus price target of $65.80, suggesting a potential upside of 127.52%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Intra-Cellular Therapies.
Intra-Cellular Therapies has a net margin of -14.07% compared to Avidity Biosciences' net margin of -2,772.45%. Intra-Cellular Therapies' return on equity of -9.93% beat Avidity Biosciences' return on equity.
Intra-Cellular Therapies received 365 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 67.67% of users gave Avidity Biosciences an outperform vote while only 67.53% of users gave Intra-Cellular Therapies an outperform vote.
Intra-Cellular Therapies has higher revenue and earnings than Avidity Biosciences. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.
Intra-Cellular Therapies has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.
In the previous week, Intra-Cellular Therapies had 25 more articles in the media than Avidity Biosciences. MarketBeat recorded 29 mentions for Intra-Cellular Therapies and 4 mentions for Avidity Biosciences. Intra-Cellular Therapies' average media sentiment score of 0.29 beat Avidity Biosciences' score of 0.21 indicating that Intra-Cellular Therapies is being referred to more favorably in the media.
92.3% of Intra-Cellular Therapies shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 3.7% of Avidity Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Intra-Cellular Therapies beats Avidity Biosciences on 11 of the 19 factors compared between the two stocks.
Get Avidity Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avidity Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:RNA) was last updated on 1/20/2025 by MarketBeat.com Staff
Free RNA Stock Alerts